James Stoll is an Associate Professor in the Department of Pharmaceutical Sciences at Texas Tech University Health Sciences Center School of Pharmacy in Amarillo, Texas, a position he has held continuously since July 1996. His educational background includes a PhD in Biochemistry from Johns Hopkins University School of Public Health (1980-1987) and a BS in Chemistry from New Mexico State University (1977-1980). Dr. Stoll's research focuses on neuroscience and biochemistry with specialized expertise in Down syndrome and Alzheimer's disease pathophysiology. He has pioneered work using Ts65Dn mouse models to investigate cognitive impairment mechanisms, mitochondrial dysfunction (particularly cytochrome oxidase deficiencies), and neurotransmitter system alterations. His pharmacological studies span ion channel regulation , blood-brain barrier transporters , and dietary interventions for neurological disorders. Analysis of his 27 publications reveals consistent investigation of neurodegenerative mechanisms across two decades, with particular emphasis on calcium/sodium channel expression in trisomy models and metabolic therapies for seizure disorders. His work demonstrates rigorous biochemical methodology applied to complex neurological questions.
Robert J. McDonald is an Associate Professor of Psychology and Neuroscience at the University of Lethbridge, where he holds a Canada Research Chair. He is affiliated with the Department of Psychology and Neuroscience and is part of the faculty at the Canadian Centre for Behavioural Neuroscience (CCBN). Dr. McDonald received his BSc from the University of Lethbridge, followed by an MSc and PhD in Psychology from McGill University in Montreal, Quebec. After completing postdoctoral training at the University of New Mexico on a NSERC post-doctoral fellowship, he joined the Department of Psychology at the University of Toronto where he received tenure in 2000. He later returned to Lethbridge to take his current position. Dr. McDonald's research focuses on understanding interactions among learning and memory systems, the role of memory system dysfunction in psychiatric disorders, testing alternative theories of Alzheimer's disease, co-factors contributing to cognitive and motor deficits following stroke, and multiple pathways for memory consolidation. His work primarily uses rodent models to investigate these questions, with particular emphasis on how different brain regions contribute to various forms of learning and memory. Analysis of his recent publications reveals consistent investigation of hippocampal-striatal interactions, stress effects on memory, and mechanisms underlying Alzheimer's disease pathology and stroke recovery. Dr. McDonald has been recognized with a Canada Research Chair, highlighting his significant contributions to neuroscience research. His publication record demonstrates sustained productivity with numerous high-impact papers in leading neuroscience journals from 2007-2011. While specific information about his advising is limited in the provided text, his extensive publication record with multiple co-authors, particularly N.S. Hong and L.A. Craig, suggests active mentorship of graduate students and research collaborators. His Canada Research Chair position indicates successful grant funding to support his laboratory operations. Dr. McDonald is an integral part of the research team at the Canadian Centre for Behavioural Neuroscience (CCBN), where he conducts rodent-based neuroscience research investigating fundamental questions about brain function and memory processes.
Dr. David B. Jacoby is a Professor in the Department of Medicine and Department of Chemical Physiology and Biochemistry at Oregon Health & Science University (OHSU) School of Medicine. Previously serving as Dean of the School of Medicine (2022-2024) and Chair of the Department of Medicine (2018-2021), he remains a tenured faculty member specializing in Pulmonary and Critical Care Medicine. Board-certified in Internal, Pulmonary, and Critical Care Medicine, his clinical and research leadership spans over three decades with significant contributions to airway disease mechanisms. Education B.A., Princeton University, 1976 M.D., New York Medical College, 1980 Residency in Internal Medicine, Temple University Hospital, 1981-1983 Fellowship in Clinical Pulmonary, University of California, San Francisco, 1984-1985 Fellowship in Pulmonary Research, Cardiovascular Research Institute, UCSF, 1985-1987 Dr. Jacoby's research program pioneers the neuroimmunological basis of airway diseases, focusing on how eosinophils interact with airway nerves to drive hyperresponsiveness in asthma and chronic cough. His work reveals critical developmental programming mechanisms where maternal/grandmaternal exposures (diet, allergens) epigenetically alter offspring airway innervation and reactivity. Key investigations examine obesity-diet interactions with neural remodeling and identify novel pathways for bronchoconstriction regulation. Analysis of his 2020-2025 publications demonstrates consistent innovation in airway neuroscience methodology and conceptual frameworks. Dominant themes include eosinophil-mediated neural plasticity, transgenerational epigenetic inheritance of airway disease, and metabolic-neural crosstalk in obesity-related asthma. His team frequently employs advanced techniques like multicolor neuronal labeling and optogenetics to dissect parasympathetic heterogeneity and sensory reflex arcs, with strong translational emphasis on therapeutic target identification. Dr. Jacoby maintains active research within OHSU's Division of Pulmonary and Critical Care Medicine, leading a collaborative team that includes Allison D. Fryer and Matthew G. Drake. His laboratory integrates molecular, cellular, and physiological approaches to investigate airway neural biology, with particular focus on how immune cells remodel neural circuits in chronic respiratory diseases. Current work explores novel interventions targeting neural-immune interactions for treatment-resistant asthma and chronic cough.
Professor Alison Yarnall is a neurology researcher at Newcastle University, specializing in Parkinson's disease, cognitive impairment, and neurodegenerative disorders. Her work focuses on gait analysis, wearable sensor technologies, and clinical outcomes in neurodegenerative conditions. She leads the Mobilise-D consortium and collaborates on studies like the Exenatide-PD3 clinical trial. Her research addresses delirium detection, cholinergic dysfunction, and motor symptom management in Parkinson's patients. She has pioneered real-world gait monitoring and validated digital health tools for medication adherence. Her multidisciplinary approach integrates engineering, neuroscience, and clinical practice to improve diagnostic accuracy and therapeutic interventions. Affiliations: Newcastle University (Neurology focus) Key projects: Mobilise-D, ICICLE-PD cohort studies Research emphases: Wearable sensors, Parkinson's biomarkers, cognitive decline prediction Her research interests include the interplay between cholinergic systems and postural control, the role of digital mobility outcomes in clinical trials, and the neuroimaging correlates of cognitive impairment. She has published extensively on gait analysis, delirium in Parkinson's patients, and the application of machine learning in neurological monitoring. Notable contributions include developing energy-based indices for motor state assessment and advancing Delphi-method protocols for patient-centered digital health design. Her work bridges clinical practice and technological innovation, aiming to improve patient outcomes through precise monitoring and early intervention strategies.
Associate Professor Rebecca Lim is an academic at the University of Newcastle’s School of Biomedical Sciences and Pharmacy, specializing in Anatomy. She holds an Associate Professorship and serves as a Chief Investigator in vestibular research. Her work focuses on balance mechanisms, auditory systems, and the functional development of vestibular hair cells and neurons. Lim collaborates globally with vestibular experts and is affiliated with HMRI neuroscientists. She supervises multiple PhD students and coordinates the Anatomy course for Biomedical Sciences. Additionally, she is a faculty member of the Australian Course in Advanced Neuroscience (ACAN), training early-career researchers. Education: PhD (Australian National University) Bachelor of Science (Honours) and Bachelor of Science (University of Newcastle) Research Interests: Lim’s research explores sensory neurobiology, particularly the vestibular system’s central and peripheral components. She employs immunofluorescent labeling and microscopy to study neuronal proteins in the inner ear and brain. Her recent work includes NHMRC-funded studies on vestibular hair cell development and the role of central vestibular neurons in postural control. She investigates aging effects on vestibular function and motion sickness susceptibility, leveraging mouse models to dissect synaptic and circuit-level mechanisms. Publications & Grants: Lim has authored over 70 articles, including studies on efferent vestibular system anatomy, neurofilament changes in Parkinson’s disease, and organoid models of reproductive systems. She secured NHMRC grants totaling ~$4.1M for projects like targeting vestibular schwannoma, efferent system therapies for balance disorders, and bioelectronic neural interfaces. Current grants focus on drug delivery systems and precision neuromodulation. Teaching & Outreach: Besides undergraduate anatomy and neuroscience courses, Lim mentors third-year research students and oversees thesis supervision. Her ACAN role emphasizes advanced neuroscience training for early researchers. Labs & Collaborations: Lim’s research integrates with Hunter Medical Research Institute (HMRI) and international teams. She uses cutting-edge techniques like rotary cell culture systems for inner ear organoids and organic semiconductor-based neural interfaces to bridge basic science with clinical applications in balance disorders.
Dzung Do-Ha is an Associate Research Fellow at the School of Chemistry and Molecular Bioscience, University of Wollongong, Australia. Their research focuses on neurodegenerative diseases including ALS/FTD, Alzheimer’s disease, and vanishing white matter disease. They specialize in developing induced pluripotent stem cell (iPSC) models to study disease mechanisms and identify therapeutic targets. Dr. Do-Ha leads projects involving cellular modeling, drug repurposing, and advanced imaging techniques. Current research interests include investigating ubiquitin proteasome system dysfunction in motor neurons, astrocyte-neuron interactions in neurodegeneration, and developing high-throughput screening platforms for cytoprotective drugs. They also explore biomolecular condensates as novel biomaterials and apply computational methods like deep learning for electrophysiological signal analysis. Dr. Do-Ha has secured funding for equipment upgrades (e.g., IncuCyte SX5 live cell imaging) and optogenetic tools for MND research. They currently supervise three PhD students focusing on Alzheimer’s disease microglial function, ALS astrocyte roles, and neural progenitor cell guidance engineering. Key achievements include pioneering iPSC differentiation protocols for cholinergic neurons and identifying cytoprotective drugs for vanishing white matter disease. Their work bridges stem cell biology, computational modeling, and translational drug discovery to address unmet clinical needs in neurodegenerative disorders.
Professor Vincent O'Connor is a Professor of Neurochemistry in the Department of Biological Sciences at the University of Southampton. His research focuses on synaptic function/dysfunction, neurodegeneration, and translational neurobiology using C. elegans as a model organism. He has held academic positions since 1999, progressing from Lecturer to Professor. His work integrates molecular biology, genetics, and pharmacology to address clinical challenges such as organophosphate poisoning and neurodegenerative diseases. Research Interests: Molecular mechanisms of synaptic biology, genetic models of neuronal dysfunction, and drug development targeting synaptic proteins. Current projects include neurodegeneration studies, antihelminthic drug discovery, and organophosphate intoxication mitigation strategies. Teaching Contributions: Contributes to undergraduate/postgraduate programs in Neuroscience, Pharmacology, and Molecular Biology. Leads advanced modules like Advanced Neuroscience (Biol 6084) and supervises BSc/MSc research projects. Grants and Collaborations: Principal investigator on projects funded by MRC, BBSRC, Alzheimer's Society, and industry partners like Bayer Animal Health. Active in interdisciplinary initiatives such as the Neuroscience Institute for Life Sciences.
Björn Granseth is an Associate Professor at Linköping University's Department of Biomedical and Clinical Sciences (BKV), affiliated with the Faculty of Medicine and Health Sciences. He holds the title of Docent and is part of the Division of Cell and Neurobiology. His research focuses on neural circuits, synaptic plasticity, and neurotransmitter modulation, particularly in corticothalamic communication and motivational processes. Granseth is affiliated with the Wallenberg Centre for Molecular Medicine (WCMM) and the Center for Social and Affective Neuroscience (CSAN). His work explores cholinergic and noradrenergic modulation of synaptic inputs, VGluT1's role in visual attention, and striatal melanocortin receptors' influence on motivational valence. Key techniques include genetic mouse models (Ntsr1-Cre GN220) and in vitro electrophysiological studies. Granseth collaborates on projects involving neuropharmacology (e.g., Sigma-2 receptor agonists) and developmental biology (Hedgehog signaling in Drosophila). Recent articles highlight contributions to understanding corticothalamic synapses, synaptic plasticity deficits in VGluT1-deficient mice, and the neurobiology of reward circuits. His research bridges basic neuroscience with clinical implications, particularly in neurological disorders.
Dr. Matthew Broadhead is a Research Fellow at the University of St Andrews' School of Psychology and Neuroscience. He holds a PhD from the University of Edinburgh (2015) and a BSc in Neuroscience from the University of Manchester (2012). His research focuses on astrocytes' role in spinal cord neuronal networks, particularly in modulating rhythmic locomotor activity and synaptic communication in neurodegenerative diseases like ALS. Using advanced microscopy and chemic-genetic tools, he investigates astrocyte-neuron interactions and synaptic pathology. He supervises three PhD students and has received awards including the 2024 Best Talk Award at the Scottish Microscopy Symposium and the 2023 ECR Presentation Award from the Scottish Neuroscience Group. Key research areas include neuroglial interactions, spinal cord physiology, and ALS mechanisms. Broadhead collaborates with institutions like the Institute of Behavioural and Neural Sciences and has secured grants from the Wellcome Trust and Chief Scientist Office. His work contributes to Sustainable Development Goals related to health and well-being through advancements in neurodegenerative disease research.
Choongheon Lee is an Assistant Professor of Research in the Department of Mechanical Engineering at the University of Rochester’s Hajim School of Engineering & Applied Sciences. His research focuses on understanding vestibular and auditory system functions, with particular emphasis on peripheral vestibular function assessment, inner ear drug delivery, and pharmacological interventions for hearing and balance disorders. His work integrates biomechanical, electrophysiological, and pharmacological approaches to study inner ear physiology and develop therapeutic strategies. Education details are not explicitly listed in the provided information, but his current academic role reflects advanced training in biomedical engineering or related fields. Research interests include drug delivery mechanisms in the inner ear, pharmacological modulation of vestibular responses, and the neurobiology of hearing disorders. He employs animal models such as guinea pigs and mice to investigate endolymphatic hydrops, cochlear synapse loss, and the effects of therapeutic agents on sensory pathways. His recent publications explore topics such as cochlear fluid dynamics, the role of KCNQ2/3 ion channels in vestibular function, and the impact of CGRP on sensory hypersensitivity. While no awards are explicitly mentioned, his active research portfolio indicates contributions to understanding balance and hearing mechanisms. Advising and grant details are not provided in the text, though his involvement in collaborative projects and experimental setups suggests potential interdisciplinary collaborations. Lee’s work is closely tied to laboratory research within the Hajim School, focusing on translational studies that bridge basic science and clinical applications in audiology and vestibular medicine.
Peter Campochiaro is a Professor of Ophthalmology at the Johns Hopkins School of Medicine, Department of Ophthalmology, where he conducts cutting-edge research on retinal diseases. He is affiliated with the Neuroscience Training Program and the Visual Neuroscience Training Program, reflecting his interdisciplinary approach. His research focuses on the neurobiology of retinal degeneration, particularly retinitis pigmentosa (RP) and age-related macular degeneration (AMD). He investigates the role of oxidative stress in secondary cone death in RP and the transition to neovascular AMD, exploring therapeutic strategies such as antioxidant supplementation and gene therapy to enhance endogenous defense systems. His recent publications demonstrate a strong trend in developing sustained delivery systems for anti-VEGF agents, gene therapy vectors (AAV), and nonviral nanoparticles for suprachoroidal delivery. His work spans basic science, translational models, and clinical trials, especially in diabetic macular edema and neovascular AMD. Professor of Ophthalmology, Johns Hopkins University Research focus: Oxidative stress, retinal degeneration, gene therapy Active in clinical trials for sustained ocular drug delivery Scientific Awards: No awards explicitly mentioned in the provided text. Advising and Grants: Dr. Campochiaro mentors numerous graduate students and postdoctoral researchers, many of whom appear as co-authors on his publications. His research is supported by extensive grant funding, evident from multi-center clinical trials and advanced therapeutic development projects, particularly in ocular gene therapy and drug delivery systems. Labs and Teams: He leads a research team focused on molecular aspects of retinal repair and regeneration, collaborating with experts in biomaterials, nanotechnology, and computational modeling to innovate ocular therapeutics.
Paul O'Connor is a Professor in the Department of Physiology at the Medical College of Georgia, Augusta University. He holds a joint appointment in the Department of Medicine: Experimental Medicine and leads a dynamic research laboratory focused on renal physiology and hypertension. He earned his PhD in Physiology from Monash University, Australia, and completed postdoctoral training at the Medical College of Wisconsin. PhD, Physiology, Monash University, 2005 BSc (Hons), Biomedical Science, Monash University, 2001 Post-doctoral Fellow, Physiology, Medical College of Wisconsin, 2005–2009 Dr. O'Connor’s research centers on the physiological regulation of kidney function, particularly in the context of hypertension and chronic kidney disease (CKD). His laboratory investigates mechanisms such as renal oxygenation, vascular congestion, and the role of the cholinergic anti-inflammatory pathway in kidney protection. A major focus is on how oral sodium bicarbonate ingestion modulates systemic inflammation via the spleen, offering potential low-cost therapies for autoimmune and inflammatory diseases. His work also explores the function of voltage-gated proton channels (Hv1) in oxidative stress and salt-sensitive hypertension. The most recent publications reveal a strong trend toward understanding the interplay between renal microvascular dysfunction, immune regulation, and metabolic interventions. His team frequently uses Dahl salt-sensitive rat models and integrates in vivo physiology with molecular and cellular techniques. The articles span topics from the role of mesothelial cells in splenic signaling to genetic factors protecting against age-related CKD, indicating a highly interdisciplinary and translational research program. Dr. O'Connor has received numerous honors, including: Arthur C. Guyton Award for Excellence in Integrative Physiology (American Physiological Society, 2015) Distinguished Faculty Award for Basic Science Teaching (Medical College of Georgia, 2019) Excellence in Teaching Award (Augusta University Graduate School, 2018) Elected Fellow, American Heart Association (2013) Patent Award for compositions involving oral alkaline salts (2022) He has successfully mentored numerous graduate students, research associates, and undergraduate honors students. His lab receives significant funding from the NIH, including grants from NIDDK and NIAID, supporting projects on mesothelial signaling and red blood cell trapping in kidney injury. Dr. O'Connor is actively involved in institutional service as Co-Director of the Physiology Graduate Program and serves on multiple national grant review panels (NIH, AHA, VA). He is also an editorial board member for American Journal of Physiology-Renal and Physiological Reports , and served as Associate Editor for Molecular Medicine and Comprehensive Physiology . His lab is located in the Health Sciences Campus, with ongoing collaborations with researchers in Australia and across the U.S.
Mia Ericson is a Professor at the Section of Psychiatry and Neurochemistry and Vice Dean of the Sahlgrenska Academy, University of Gothenburg. Her research group, 'Addiction Medicine', investigates neurochemical mechanisms of substance dependence using rodent models. Her work centers on dopamine, glycine, and taurine dynamics in addiction, with emphases on alcohol and nicotine effects on striatal circuitry. Key research areas include neuroadaptations during withdrawal, astrocyte-neuron interactions, and pharmacological interventions targeting glutamate/GABA systems. Recent publications (2022-2025) demonstrate a focus on: Neuroimmune interactions in opioid/alcohol dependence Sex-specific neuroadaptations in nicotine/amphetamine withdrawal Glycine transporter inhibition as a therapeutic strategy Astrocytic modulation of synaptic plasticity
Dr. George Howell III is an Associate Professor at Mississippi State University College of Veterinary Medicine, affiliated with the Center for Environmental Health Sciences. His research investigates the impact of environmental exposures—particularly persistent organic pollutants and pesticides—on metabolic dysfunction, obesity, and Type 2 diabetes. He employs both in vitro and in vivo models to study mechanisms like lipid accumulation, RAGE signaling, and wound healing impairments in diabetic conditions. Doctor of Philosophy (Ph.D.), Pharmacology/Toxicology, University of Mississippi Medical Center (2007) Bachelor of Science (B.S.), Microbiology, Mississippi State University (2000) Current research focuses on the interplay between pesticide exposure and downstream metabolic diseases, including cardiovascular remodeling, hepatic steatosis, and adipose tissue inflammation. His work also explores how these exposures exacerbate complications in diabetic models. Recent publications highlight pesticide-induced alterations in lipid metabolism, glucose homeostasis, and immune responses in obesity-diabetes contexts. Articles span journals like Environmental Toxicology , Toxicology in Vitro , and Toxicological Sciences , emphasizing interdisciplinary environmental health research. He is actively involved in the Center for Environmental Health Sciences, contributing to projects linking environmental toxicants to chronic disease susceptibility. No formal advisees or scientific awards are explicitly listed in the provided materials.
Stephen D. Ginsberg, PhD, is a Professor in both the Department of Psychiatry and Department of Neuroscience at NYU Grossman School of Medicine. His research focuses on molecular and cellular mechanisms underlying neurodegenerative disorders, particularly Alzheimer's disease and Down syndrome. PhD from Mount Sinai School of Medicine Fellowship at Johns Hopkins University School of Medicine (Division of Neuropathology) Fellowship at University of Pennsylvania School of Medicine (Center for Neurodegenerative Disease Research) His work integrates digital spatial profiling , single-cell transcriptomics , and proteomics to study neuronal subtypes, gene expression mosaics, and connectivity-based degeneration patterns. Recent publications examine microRNA dysregulation, cholinergic mechanisms in Alzheimer's disease, and systems-level protein interaction dysfunction. Current affiliations include NYU Langone Health, where he investigates neurodegenerative pathogenesis and translational neuroscience . His laboratory develops computational platforms like dfPPI for analyzing protein-protein interaction networks in disease states.
